Hepatitis C-related liver disease in dialysis patients

Area of Science:

• Nephrology
• Hepatology
• Infectious Diseases

Background:

• Hepatitis C virus (HCV) is a leading cause of liver damage in chronic kidney disease (CKD) patients, particularly those on long-term dialysis.
• The natural history and survival impact of HCV in CKD patients on dialysis require further elucidation.
• HCV infection is linked to diminished survival, impaired quality of life, and increased cardiovascular disease risk in dialysis patients.

Purpose of the Study:

• To summarize the current understanding of Hepatitis C virus infection in patients with chronic kidney disease on dialysis.
• To analyze the impact of HCV on mortality and disease progression in this vulnerable population.
• To explore potential mechanisms for slower HCV liver disease progression in dialysis patients.

Main Methods:

• Meta-analysis of seven observational studies involving 11,589 dialysis patients.
• Analysis of adjusted relative risk for all-cause mortality associated with anti-HCV antibody.
• Review of data on liver-related mortality, hepatocellular carcinoma, and liver cirrhosis incidence.

Main Results:

• A meta-analysis reported an adjusted relative risk of 1.34 for all-cause mortality in anti-HCV antibody-positive dialysis patients.
• Hepatocellular carcinoma and liver cirrhosis were significantly more frequent in anti-HCV-positive patients.
• Liver-related mortality risk was substantially higher (unadjusted risk 5.89) in HCV-infected dialysis patients.

Conclusions:

• HCV infection poses a significant mortality risk for dialysis patients, primarily due to liver disease and cardiovascular complications.
• Despite immune compromise in uremia, HCV-related liver disease progression may be slower in dialysis patients.
• Mechanisms, including potential viral load reduction during hemodialysis, warrant further investigation.